SCHEMBL2863698

SCHEMBL2863698

CCc1cc(Br)ccc1OCC(C)(C)[SiH](C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
HTT P42858 1/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.40
CCR5 P51681 5/20 0.40
GAA P10253 2/20 0.40
ALDH1A1 P00352 2/20 0.39
NPY1R P25929 1/20 0.39
NPY2R P49146 1/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
GLA P06280 1/20 0.38
RAB9A P51151 3/20 0.38
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2287091 0.81 AAK1 (0.47) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL12144678 0.81 PTGDR2 (0.45) KMT2AMEN1HTTPTGDR2CCR5
SCHEMBL4816613 0.80 SMN1; SMN2 (0.42) KMT2AMEN1HTTPTGDR2GAA
SCHEMBL22208677 0.80 TSHR (0.46) KMT2AMEN1ALDH1A1LMNASMN1; SMN2
SCHEMBL941193 0.80 GLA (0.42) KMT2AMEN1HTTPTGDR2GAA
SCHEMBL17316744 0.80 SLC6A4 (0.43) KMT2AMEN1HTTPTGDR2CCR5
SCHEMBL6448158 0.79 PTGDR2 (0.43) KMT2AMEN1HTTPTGDR2CCR5
SCHEMBL15208869 0.78 CYP2C9 (0.41) KMT2AMEN1HTTPTGDR2CCR5
SCHEMBL4471856 0.78 SMN1; SMN2 (0.32) LMNASMN1; SMN2GLAHPGDL3MBTL1
SCHEMBL14992970 0.77 HTR2A (0.36) KMT2AMEN1HTTPTGDR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR KMT2A 4353/4885MEN1 945/4885HTT 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.